- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 06.11. | Spago Nanomedical Interim Report January-September 2024 | 159 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / November 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Progress for the Tumorad programJULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 485 (KSEK... ► Artikel lesen | |
| 21.10. | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2025 | 169 | ACCESSWIRE | LUND, SE / ACCESSWIRE / October 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen | |
| 01.10. | Spago Nanomedical in New Phase with Full Focus on the Tumorad Program | 225 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB (publ) has decided that the company's resources will be focused... ► Artikel lesen | |
| 18.09. | Four-hands Dinner at Spago Budapest | 1 | BBJ online | ||
| 05.09. | Spago Nanomedical strengthened management to reflect project progress | 2 | Cision News | ||
| 27.08. | Spago Nanomedical's Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group | 281 | ACCESSWIRE | LUND, SE / ACCESSWIRE / August 27, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that the independent Data Monitoring Committee (DMC) recommends to proceed... ► Artikel lesen | |
| 21.08. | Spago Nanomedical Interim Report January-June 2024 | 276 | ACCESSWIRE | LUND, SE / ACCESSWIRE / August 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Clinical and non-clinical progress in the Tumorad program APRIL - JUNE IN BRIEFNet sales for the quarter amounted... ► Artikel lesen | |
| 10.06. | Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB | 220 | ACCESSWIRE | LUND, SE / ACCESSWIRE / June 10, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, June 10, 2024, at which the AGM resolved... ► Artikel lesen | |
| 23.05. | Spago Nanomedical Receives Declarations of Intent from the Largest Owner, Board and Management Team Regarding the Exercise of TO12 | 255 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / May 23, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") has received declarations of intent from, among... ► Artikel lesen | |
| 20.05. | Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned | 501 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / May 20, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that both of the clinical sites in the phase I/IIa study Tumorad-01... ► Artikel lesen | |
| 17.05. | The Exercise Period for Spago Nanomedical's Warrants of Series TO12 Commences Today | 378 | ACCESSWIRE | LUND, SE / ACCESSWIRE / May 17, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") issued a total of 127,321,212 warrants of series... ► Artikel lesen | |
| 16.05. | Spago Nanomedical Publishes the Annual Report for 2023 | 246 | ACCESSWIRE | LUND, SE / ACCESSWIRE / May 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2023 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 06.05. | Notice To Annual General Meeting of Spago Nanomedical AB | 277 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / May 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the annual general meeting is for convenience only. The Swedish version prevails... ► Artikel lesen | |
| 02.05. | Spago Nanomedical Interim Report January-March 2024 | 354 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / May 2, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Positive start to an important yearJANUARY - MARCH IN BRIEFNet sales for the quarter amounted to KSEK 350 (KSEK... ► Artikel lesen | |
| 24.04. | Spago Nanomedical Reports Favorable Data in Breast Cancer Model with Tumorad | 555 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / April 24, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today data from a non-clinical study exploring 177Lu-SN201 in a model for... ► Artikel lesen | |
| 16.04. | Spago Nanomedical Strengthens Management with Head of CMC & Supply | 298 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / April 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced the appointment of Birgitta Rembratt Svensson as Head of CMC & Supply.... ► Artikel lesen | |
| 07.02. | Spago Nanomedical Year-end Report January-December, 2023 | 357 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / February 7, 2024 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) First cancer patient dosed with Tumorad®OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK... ► Artikel lesen | |
| 18.01. | Spago Nanomedical Presents at Redeye's Fight Cancer Event on January 24 | 298 | ACCESSWIRE | LUND, SWEDEN / ACCESSWIRE / January 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company will participate at Redeye's Fight Cancer event... ► Artikel lesen | |
| 10.01. | Spago Nanomedical Proceeds to the Next Dose Level in the Phase I/IIa Study Tumorad-01 | 477 | ACCESSWIRE | LUND, SE / ACCESSWIRE / January 10, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent data monitoring committee has recommended a dose... ► Artikel lesen | |
| 20.12.23 | Nasdaq Stockholm AB: New equity right for trading, Spago Nanomedical AB (682/23) | 312 | GlobeNewswire | At the request of Spago Nanomedical AB, Spago Nanomedical AB equity right will
be traded on First North as from December 21, 2023.
Security name: Spago Nanomedical AB TO 12
------------------------------------------
Short... ► Artikel lesen |
Seite:
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,475 | -0,48 % | QIAGEN N.V.: QIAGEN führt neuartige Tools zur Anpassung von digitalen PCR-Assays und NGS-Panels für die mikrobielle Analyse ein | QIAGEN führt das erste Design-Tool für individuell anpassbare digitale PCR-Assays im Markt ein, ausgestattet mit fortschrittlichen Design-Algorithmen für verschiedene mikrobielle Anwendungen und kundenspezifische... ► Artikel lesen | |
| EVOTEC | 8,585 | -3,86 % | wO Börsenlounge: Amazon | Hugo Boss | Evotec - nach Chipotle explodiert ein ganz neuer Wert! | Die Erfolgsgeschichte von Chipotle Mexican Grill ist zuletzt etwas ins Stocken geraten. Dafür springt ein neuer Wert in die Bresche. Seit Jahresanfang legt die Aktie um 200 Prozent zu und das dürfte... ► Artikel lesen | |
| JANUX THERAPEUTICS | 62,22 | +55,01 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| BIONTECH | 111,50 | -0,09 % | Evotec, Vidac Pharma, BioNTech - Krebsforschung: Die Goldgrube im Depot | Investitionen in Aktiengesellschaften, die im Bereich der Onkologieforschung tätig sind, bieten vielversprechende Renditechancen und langfristige Stabilität. Der Onkologiemarkt gehört zu den wachstumsstärksten... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,270 | -4,03 % | Recursion Pharmaceuticals, Inc.: Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to result from end-to-end use of OS to identify a novel target and new chemical matter, which moved from target ID to IND enabling studies in under 18 months with ~200 compounds synthesizedREC-1245... ► Artikel lesen | |
| CITIUS ONCOLOGY | 1,410 | +38,24 % | Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA) and LYMPHIR in Cancer Patients ... | Study, in patients with solid tumors focusing on gynecological malignant tumors such as ovarian, endometrial, and cervical, nearing completion with three remaining subjects to be enrolled27%... ► Artikel lesen | |
| VERVE THERAPEUTICS | 7,330 | +2,73 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| ADMA BIOLOGICS | 19,760 | +0,36 % | Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge | ||
| GUBRA | 91,20 | -6,56 % | AKTIONÄR-Depotwert Gubra: Nächstes Kaufsignal - neue Rekorde in Sicht | Die Bullen bleiben beim AKTIONÄR-Depotwert Gubra am Drücker. Zum Start in die neue Handelswoche strebt die Aktie des dänischen Wirkstoffforschers an der Heimatbörse in Kopenhagen auf ein neues Verlaufshoch... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,220 | -1,41 % | Summit Therapeutics Aktie: Verunsicherung steigt! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnet einen bemerkenswerten Aufschwung an der Börse. Die Aktie schloss am 9. November 2024 bei 21,41 USD, was einem Anstieg von 1,47%... ► Artikel lesen | |
| SENTI BIOSCIENCES | 7,370 | -27,10 % | Senti Biosciences, Inc.: Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory ... | - 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile - - Dose escalation is continuing with additional... ► Artikel lesen | |
| CABALETTA BIO | 3,675 | -10,69 % | Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update | - Nine patients enrolled as of August 5, 2024 across the RESET clinical development program, including four since EULAR in June, with 22 U.S. clinical sites now enrolling - - Additional clinical data... ► Artikel lesen | |
| COHERUS | 1,762 | +35,45 % | Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M | ||
| BB BIOTECH | 40,350 | -0,12 % | BB Biotech Aktie: Klare Gewinne sichtbar! | ||
| AMGEN | 265,55 | +0,26 % | Opening Bell: Bitcoin, Amgen, Eli Lilly, The GEO Group, Amazon, Ebay, Walmart, Archer Aviation | Der Start in die neue Woche kann sich für die Wall Street sehen lassen. Der Dow Jones und der S&P 500 erreichten gestern neue Bestmarken. Heute deutet sich bei den großen Indizes ein verhaltener Start... ► Artikel lesen |
Das Unternehmen SPAGO NANOMEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -1,45 % bei einem Aktienkurs von 0,014 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.
